Drug Approval | March 21, 2022
Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Subscribe To Our Newsletter & Stay Updated
